Cookie Policy: This site uses cookies to improve your experience. You can find out more about our use of cookies in our Privacy Policy. By continuing to browse this site you agree to our use of cookies.
SynKinase
XL765
CHF 0.00
In stock
SYN-1137-M0011 mgCHF 177.00
SYN-1137-M0055 mgCHF 298.00
SYN-1137-M01010 mgCHF 454.00
SYN-1137-M05050 mgCHF 1'483.00
SYN-1137-M100100 mgINQ
| Product Details | |
|---|---|
| Synonyms | SAR-245409 |
| Product Type | Chemical |
| Properties | |
| Formula | C31H29N5O6S |
| MW | 599.7 |
| CAS | 1349796-36-6 |
| Purity Chemicals | ≥95% |
| Appearance | Solid. |
| Solubility | Soluble in DMSO. Slightly soluble (<1mg/ml) in ethanol. |
| Declaration | Manufactured by SynKinase. |
| Other Product Data |
Target: PI3K | Kinase Group: Lipid Kinase | Substrate: Lipid Click here for Original Manufacturer Product Datasheet Our product description may differ slightly from the original manufacturers product datasheet. |
| InChi Key | HJSSPYJVWLTYHG-UHFFFAOYSA-N |
| Shipping and Handling | |
| Shipping | AMBIENT |
| Short Term Storage | +4°C |
| Long Term Storage | -20°C |
| Use/Stability | Stable for at least 2 years after receipt when stored at -20°C. |
| Documents | |
| MSDS |
 Download PDF |
| Product Specification Sheet | |
| Datasheet |
Download PDF |
Description
XL765 is active against class I PI3K (IC(50) = 39, 113, 9 and 43nM for p110α, β, γ and δ, respectively). XL765 also inhibits DNA-PK (IC(50) = 150nM) and mTOR (IC(50) = 157nM)
Product References
- Drug discovery approaches targeting the PI3K/Akt pathway in cancer. Oncogene. 27, 5511 (2008)
- Inhibition of PI3K/mTOR pathways in glioblastoma and implications for combination therapy with temozolomide: G. Prasad, et al.; Neuro Oncol. 13, 384 (2011)
Related Products
